MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
- Mechanism
- Curator reviewed
MYO-029 is used to treat muscular dystrophy. It binds to and inhibit the activity of myostatin (growth and differentiation factor 8 or GDF-8), a protein that prevents skeletal muscle formation. Muscular dystrophy is characterized by a progressive wasting and weakening of muscle fibers. The disorder can be classified into six major types, all of which are inherited. The common feature of these disorders is absence of one of several proteins involved in linking F-actin (a muscle fiber component) to the sheath of tissue surrounding the fiber.
- Primary indication
- Investigated for use/treatment in muscular dystrophy.Curator reviewed
- Also known as
- MYO 029 · MYO-029 · MYO029
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Stamulumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account